M&A Deal Summary

Renovaro Acquires Enochian Biopharma

On January 23, 2018, Renovaro acquired life science company Enochian Biopharma

Acquisition Highlights
  • This is Renovaro’s 2nd transaction in the Life Science sector.
  • This is Renovaro’s 2nd transaction in the United States.
  • This is Renovaro’s 2nd transaction in California.

M&A Deal Summary

Date 2018-01-23
Target Enochian Biopharma
Sector Life Science
Buyer(s) Renovaro
Deal Type Add-on Acquisition

Target

Enochian Biopharma

Los Angeles, California, United States
Enochian Biopharma, Inc. is a developer of an innovative proprietary technology in the field of HIV/AIDS. Enochian Biopharma is based in Los Angeles, California.

Search 214,503 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Renovaro

Los Angeles, California, United States

Category Company
Founded 2011
Sector Life Science
Employees10
DESCRIPTION

Renovaro is a biotechnology company focused on developing innovative platforms for gene-modified cellular and immune therapies to cure and treat diseases that kill millions of people each year. Renovaro' VIVA, a Phase III clinical trial MCV is adjuvant immunotherapy that is designed to prevent colon cancer recurrence after standard of care surgery and chemotherapy. Renovaro was founded in 2011 and is based in Los Angeles, California.


DEAL STATS #
Overall 2 of 2
Sector: Life Science M&A 2 of 2
Type: Add-on Acquisition M&A Deals 2 of 2
State: California M&A 2 of 2
Country: United States M&A 2 of 2
Year: 2018 M&A 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2016-04-05 OncoSynergy

San Francisco, California, United States

OncoSynergy is a developer of novel oncology drug candidates including the first-in-class FDA orphan drug designated anti-CD29 monoclonal antibody, OS2966.

Buy -